

Cite this: *Nanoscale Adv.*, 2022, 4, 911

Green synthesis of silver nanoparticles using green tea leaf extract, characterization and evaluation of antimicrobial activity

Hiba Abbas Widatalla,^a Layla Fathi Yassin,^b Ayat Ahmed Alrasheid,^c Shima Abdel Rahman Ahmed,^b Marvit Osman Widdatallah,^a Sahar Hussein Eltilib^a and Alaa Abdulmoneim Mohamed^d

The use of nanoparticles in medicine, nanomedicine, is very important to diagnose and treat diseases; among the various metallic nanoparticles, silver nanoparticles (AgNPs) are very popular due to their physical, chemical, and biological properties, encompassing a range of activities such as antiviral, antifungal, anti-inflammatory, and anticancer activities. In this study, the synthesis of AgNPs was conducted by the use of a nontoxic, ecofriendly method. Green tea (GT) leaf extract was used as a reducing agent to convert silver ions into free AgNPs. The UV-vis spectrum showed a peak at 410 nm, confirming the presence of AgNPs. A Fourier-transform infrared (FTIR) analysis of the GT extract and GT AgNPs display spectra that is identical to those of polyphenols, polysaccharides, and proteins. All the vibrational peaks in the GT extract spectrum were shifted in the AgNP spectrum, becoming narrower after the encapsulation of nanoparticles. The scanning electron microscopy (SEM) images confirm the presence of AgNPs with different sizes, ranging from 15 to 33 nm. Furthermore, the antibacterial activity of the synthesized AgNPs in three different concentrations (10, 20, and 50 mg ml⁻¹) showed appreciable inhibition of bacterial growth against *Staphylococcus aureus* and *Klebsiella* sp. From the above findings, we can recommend the use of AgNPs from GT leaf extracts as an antimicrobial agent to treat chronic infections.

Received 29th June 2021
Accepted 17th December 2021

DOI: 10.1039/d1na00509j

rsc.li/nanoscale-advances

Introduction

Nanotechnology is a rapidly developing branch of science that incorporates many disciplines such as biology, chemistry, physics, food, medicine, electronics, aerospace, and medicine and it examines the design, manufacture, assembly, and characterization of materials that are smaller than 1–100 nm in size.¹ Nanoparticles are being applied in many fields of science such as medical, cosmetic, biomedical, drug/gene delivery, environmental, energy science, photoelectrochemical, and optical applications.² The wide range of uses of nanoparticles is due to their unique properties such as high surface-to-volume ratio, high surface energy, and unique mechanical, thermal, electrical, magnetic, and optical behaviors.³ The use of nanoparticles in medicine, also referred to as nanomedicine, is very

important toward the diagnosis and treatment of diseases; in addition, it is important to determine the efficacy and safety of nanoparticles within biological systems.⁴ Among the most important types of nanoparticles, metallic nanoparticles have a wide range of applications.⁵

The therapeutic efficacy of metallic nanoparticles is due to their optical property demonstrated by localized surface plasmon resonance.⁶ Among the various metal nanoparticles, silver nanoparticles (AgNPs) are very popular and have many uses in industry and biomedicine due to their physical and chemical properties in addition to their biological properties, which encompass a range of activities such as antiviral, antifungal, anti-inflammatory, and anticancer activities.⁷ Surface chemistry, size, size distribution, shape, particle morphology, particle composition, coating agglomeration, and dissolution rate are factors that affect the effectiveness of AgNPs inside biological systems.⁸

Silver is a nontoxic, safe inorganic antibacterial agent that is capable of killing about 650 types of disease-causing microorganisms.^{5,9} However, the emergence of bacterial strains resistant to metal ions has led to the search for new antibacterials.¹⁰ In 2015, the World Health Organization (WHO) published a report on a global antimicrobial resistance surveillance system concluding that it is very common for bacteria such as

^aDepartment of Pharmacology, Faculty of Pharmacy, University of Medical Sciences and Technology, Khartoum, Sudan. E-mail: hiba127@gmail.com

^bDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medical Sciences and Technology, Khartoum, Sudan

^cDepartment of Pharmacognosy, Faculty of Pharmacy, University of Medical Sciences and Technology, Khartoum, Sudan

^dDepartment of Clinical Pharmacy, Faculty of Pharmacy, University of Medical Sciences and Technology, Khartoum, Sudan



Escherichia coli, *Staphylococcus aureus*, *Shigella* sp., *Klebsiella pneumoniae*, and *Salmonella* sp. to show resistance toward one or several antibiotics as they are commonly present in communities and hospitals. The development of resistant machineries by bacteria has led to an increase in the rates of antibiotic resistance. All this motivates the search for a new alternative to conventional antimicrobials and antibiotics.^{10–12}

Different methods have been developed for the synthesis of nanoparticles, and each method has its own advantages and disadvantages.¹³ There are physical and chemical methods for the synthesis of metallic nanoparticles. Although these methods produce particles of the desired characteristics, they usually involve high cost, require effort, and are potentially dangerous and toxic to the environment and living organisms. To overcome the shortcomings of these physical and chemical methods, the biological approach has been used to synthesize nanoparticles. Several biological resources such as plant extracts, microorganisms, milk, oilcake, and *panchagavya* have been used as alternatives to synthesize metal nanoparticles.^{14,15} Among the various green sources explored, microalgae provide worthwhile benefits with respect to their ease of growth and their ability to survive in extreme conditions (namely, pH and temperature).¹⁶ Numerous advantages of the biological synthesis of AgNPs have been acknowledged in recent years. Various plant materials and microorganisms have been identified as potential candidates for AgNPs synthesis. It has been suggested that the presence of specific proteins in plants and microorganisms can cause the reduction of Ag⁺ ions. The probable role of NADH-dependent nitrate reductase in the reduction of Ag⁺ ions has been suggested.¹⁷

Nevertheless, the synthesis of AgNPs using plant extracts is potentially advantageous over microorganisms because of its simple scale up.¹⁸ The use of microorganisms presents several challenges such as high cost, mass cultivation of microorganisms, maintenance of an aseptic environment, purification, and quantum of production.¹⁷ On the other hand, the 'green' method that involves the use of extracts obtained from plants is cost-effective, efficient and environment-friendly.¹⁹ Several studies have been performed in recent years to synthesize nanoparticles using various plant extracts such as *Alternanthera dentata*,²⁰ *Carica papaya*,²¹ *Coffea arabica*,²² *Azadirachta indica*,²³ and *Olea europaea*.²⁴ Furthermore, plant extracts derived from various species are regarded as a beneficial system for nanoparticle synthesis due to their tremendous capability to produce a variety of phytochemicals with a profound reducing potential.²⁵ Plant metabolites like sugars, terpenoids, polyphenols, alkaloids, phenolic acids, and proteins play an important role in reducing metal ions into nanoparticles. These phytochemicals are also responsible for stabilizing the synthesized nanoparticles.²⁶

In this study, the synthesis of AgNPs was conducted by the use of green tea (GT) leaf extracts. GT leaves are known for their high content of various phytochemical constituents that are involved in the reduction of metallic ions into nanoparticles.²⁷ The synthesized AgNPs were characterized by using UV-vis spectrometry and FTIR. The morphology of the nanoparticles

was imaged by scanning electron microscopy (SEM). The antibacterial activity of the synthesized GT AgNPs was evaluated.

Materials and methods

Materials

GT sample. Dried, ground GT leaves (1 g) were obtained from a Sudanese tea company in the form of teabags (Cofftea). The teabags were purchased from a store in Khartoum, Sudan.

Reagents and analytical solutions. Deionized water, silver nitrate, sodium hydroxide, dimethyl sulfoxide (DMSO), acetone, Mueller–Hinton agar.

Methods

GT extraction. About 30 ml water were added to 1 g dried ground GT leaves. The mixture was heated for 30 min at 50 °C under magnetic stirring, then cooled and filtered.

Synthesis of GT AgNPs. Different concentrations of aqueous (GT) extracts were used to prepare the AgNPs: the concentration that afforded the best stability and yield was selected. For the preparation, 10 ml silver nitrate solution (0.01 M) were added to 20% aqueous GT extract solution in a dropwise manner, and 2.5 ml NaOH (0.1 M) were added to the mixture. The resulting solution was then heated for 30 min at 50 °C in order to increase the yield of AgNPs. Finally, the GT AgNPs were separated by centrifugation (6000 rpm) and washed with 50% acetone and allowed to dry at room temperature.

Characterization of GT AgNPs

UV spectroscopy. The UV spectra were used to ascertain the formation of AgNPs. The AgNP solution was scanned over the range of 200–400 nm by using a Shimadzu UV spectrophotometer. The dilution of GT AgNP solution was required; a ratio of 1 : 9 was used. The same dilution ratio was used for the GT extract, which acted as the reference solution.

Fourier-transform infrared (FTIR). The IR spectra of GT leaf aqueous extract and the centrifuged GT AgNPs sample were used to identify the possible chemical constituents involved in the synthesis and capping of GT AgNPs. The samples were analyzed by IRTracer-100 (Shimadzu). A pure KBr pellet was used for the background. The spectra were recorded from 400 to 4000 cm⁻¹.

Scanning electron microscopy (SEM). SEM was used to characterize the morphology and particle size of AgNPs. A thin film of oven-dried GT AgNP sample was prepared and used over a carbon-coated copper grid *via* a TESCAN MIRA-3 instrument operated at an accelerated voltage of 20 kV.

Antibacterial activity of GT AgNPs. The inhibition of bacterial growth of GTAgNPs was tested by using a disc-diffusion assay, as described by Sharma *et al.*²⁸ with certain modifications. The antimicrobial effect of GT AgNPs was tested against Gram-positive bacteria (*Staphylococcus aureus*) and Gram-negative bacteria (*Klebsiella* spp). About 20 ml Mueller–Hinton agar were poured in sterile Petri dishes to prepare the base plates. About 0.1 ml standard bacterial stock suspensions (10⁸–10⁹ cfu ml⁻¹) was streaked onto the base plates using a sterile cotton swab. A stock solution of 20 mg






Fig. 4 SEM image of the synthesized nanoparticles.

predominantly dispersed in the form of aggregates. The nanoparticles were not in direct contact with each other within the formed aggregates, which can be explained by the stabilizing action of capping agents present in the extract. These phytochemicals are known to play an active role in reducing and stabilizing metal nanoparticles.³⁴

Antibacterial activity

The antimicrobial activity of GT AgNPs has been reported in several studies.^{35–38} In this study, different concentrations (5, 10, and 20 mg ml⁻¹) of GT AgNPs were tested against *Staphylococcus aureus* and *Klebsiella* sp. As shown in Fig. 5 and 6 GT AgNPs possessed moderate activity against the tested bacteria with inhibition zone ranging between 8–11 mm. A number of theories for antimicrobial actions of silver nanoparticles solution have been proposed. Some of the proposed mechanisms include changing the permeability of the cell membrane, which enables the interaction with DNA, proteins, and other phosphorus- and sulfur-containing cell constituents that are harmful to bacteria. Another mechanism is generating free radicals responsible for the damage of membrane and dissipation of the proton motive force, resulting in the disruption of membrane potential;³⁹ however, the exact mechanism has not been fully understood. The three concentrations showed similar effectiveness in combating the tested species with the highest concentration having the highest activity. The inhibition zones obtained by GT AgNPs




Fig. 5 STD against *S. aureus* (A), GT AgNPs against *S. aureus* (B).




Fig. 6 STD against *Klebsiella* spp. (A), GT AgNPs against *Klebsiella* spp. (B).

Table 1 Antimicrobial activity of GT AgNPs

| | Zone of Inhibition in mm | |
|--|--------------------------|------------------|
| | <i>Klebsiella</i> spp. | <i>S. aureus</i> |
| GT AgNPs concentration (mg ml⁻¹) | | |
| 20 | 10 | 11 |
| 10 | 8 | 8 |
| 5 | 9 | 10 |
| Antimicrobial agent (STD) | | |
| Ciprofloxacin (5 mcg) | 26 | 32 |

were insignificant when compared to standard drug. Results shown in Table 1.

Conclusion

The synthesized silver nanoparticles were characterized using UV, FTIR and SEM. The morphology of GT AgNPs appear to be irregular and in the form of aggregates. GT AgNPs revealed antimicrobial activity against selected bacterial species. The difference in the FTIR spectra between the GT extract and GT AgNPs was used to indicate the functional groups involved in the reduction of Ag⁺ ions into nanoparticles.

Author contributions

Hiba Abbas Widatallah was responsible for conceptualization, investigation, methodology, project administration and writing the original draft.

Layla Fathi Yassin was responsible for conceptualization, investigation, methodology, project administration and writing the original draft.

Ayat Ahmed Alrasheid was responsible for conceptualization, investigation and supervision.

Shimaa Abdel Rahman Ahmed was responsible for conceptualization and investigation.

Marvit Osman Widdatallah was responsible for conceptualization and investigation.

Sahar Hussein Eltilib was responsible for conceptualization and investigation.



Alaa Abdulmoneim Mohamed was responsible for conceptualization and investigation.

Conflicts of interest

There are no conflicts to declare.

References

- 1 S. Fakhari, M. Jamzad and H. Kabiri Fard, *Green Chem. Lett. Rev.*, 2019, **12**(1), 19–24.
- 2 S. Ahmed, M. Ahmad, B. Swami and S. Ikram, *J. Adv. Res.*, 2016, **7**(1), 17–28.
- 3 G. Chen, I. Roy, C. Yang and P. Prasad, *Chem. Rev.*, 2016, **116**(5), 2826–2885.
- 4 B. Pelaz, C. Alexiou, R. Alvarez-Puebla, F. Alves, A. Andrews, S. Ashraf, *et al.*, *ACS Nano*, 2017, **11**(3), 2313–2381.
- 5 V. Kumar and S. Anthony, *Surf. Chem. Nanobiomater.*, 2016, 265–300.
- 6 M. Rai, A. Ingle, S. Birla, A. Yadav and C. Santos, *Crit. Rev. Microbiol.*, 2015, **42**, 1–24.
- 7 X. Zhang, F. Huang, G. Zhang, D. Bai, D. Massimo, Y. Huang, *et al.*, *Int. J. Nanomed.*, 2017, **12**, 7551–7575.
- 8 X. Zhang, Z. Liu, W. Shen and S. Gurunathan, *Int. J. Mol. Sci.*, 2016, **17**(9), 1534.
- 9 S. Scandorieiro, L. de Camargo, C. Lancheros, S. Yamada-Ogatta, C. Nakamura, A. de Oliveira, *et al.*, *Front. Microbiol.*, 2016, **7**, 760.
- 10 J. Firdhouse and P. Lalitha, *Prog. Biomater.*, 2015, **4**(2–4), 113–121.
- 11 B. Ramalingam, T. Parandhaman and S. K. Das, *ACS Appl. Mater. Interfaces*, 2016, **8**(7), 4963–4976.
- 12 D. M. Rudakiya and K. Pawar, *3 Biotech*, 2017, **7**(2), 1–2.
- 13 M. Kim, S. Osone, T. Kim, H. Higashi and T. Seto, *KONA Powder Part. J.*, 2017, **34**, 80–90.
- 14 M. Govarthan, M. Cho, J. H. Park, J. S. Jang, Y. J. Yi, S. Kamala-Kannan and B. T. Oh, *J. Nanomater.*, 2016, **2016**, 1–6.
- 15 M. Govarthan, Y. S. Seo, K. J. Lee, I. B. Jung, H. J. Ju, J. S. Kim, M. Cho, S. Kamala-Kannan and B. T. Oh, *Artif. Cells, Nanomed., Biotechnol.*, 2016, **44**(8), 1878–1882.
- 16 J. M. Jacob, R. Ravindran, M. Narayanan, S. M. Samuel, A. Pugazhendhi and G. Kumar, *Curr. Opin. Environ. Sci.*, 2021, **20**, 100163.
- 17 K. J. Lee, S. H. Park, M. Govarthan, P. H. Hwang, Y. S. Seo, M. Cho, W. H. Lee, J. Y. Lee, S. Kamala-Kannan and B. T. Oh, *Mater. Lett.*, 2013, **105**, 128–131.
- 18 A. Sengottaiyan, R. Mythili, T. Selvankumar, A. Aravinthan, S. Kamala-Kannan, K. Manoharan, P. Thiyagarajan, M. Govarthan and J. H. Kim, *Res. Chem. Intermed.*, 2016, **42**(4), 3095–3103.
- 19 V. V. Makarov, A. J. Love, O. V. Sinitsyna, S. S. Makarova, I. V. Yaminsky, M. E. Taliansky and N. O. Kalinina, “Green” nanotechnologies: synthesis of metal nanoparticles using plants, *Acta Naturae*, 2014, **6**(1), 35–44.
- 20 D. A. Kumar, V. Palanichamy and S. M. Roopan, *Spectrochim. Acta, Part A*, 2014, **127**, 168–171.
- 21 R. Sankar, P. Manikandan, V. Malarvizhi, T. Fathima, K. S. Shivashangari and V. Ravikumar, *Spectrochim. Acta, Part A*, 2014, **121**, 746–750.
- 22 V. Dhand, L. Soumya, S. Bharadwaj, S. Chakra, D. Bhatt and B. Sreedhar, *Mater. Sci. Eng., C*, 2016, **58**, 36–43.
- 23 A. S. Saifullah, M. Ahmad, B. L. Swami and S. Ikram, *J. Radiat. Res. Appl. Sci.*, 2016, **9**(1), 1–7.
- 24 M. M. Khalil, E. H. Ismail, K. Z. El-Baghdady and D. Mohamed, *Arabian J. Chem.*, 2014, **7**(6), 1131–1139.
- 25 F. Ameen, S. AlYahya, M. Govarthan, N. Aljahdali, N. Al-Enazi, K. Alsamhary, W. A. Alshehri, S. S. Alwakeel and S. A. Alharbi, *J. Mol. Struct.*, 2020, **1202**, 127233.
- 26 K. Parveen, V. Banse and L. Ledwani, *AIP Conf. Proc.*, 2016, **1724**, 020048.
- 27 S. K. Nune, N. Chanda, R. Shukla, K. Katti, R. R. Kulkarni, S. Thilakavathy and K. V. Katti, *J. Mater. Chem.*, 2009, **19**(19), 2912–2920.
- 28 V. Sharma, C. Chotia, V. Ganesan and G. S. Okram, *Phys. Chem. Chem. Phys.*, 2017, **19**, 14096–14106.
- 29 E. Petryayeva and U. J. Krull, *Anal. Chim. Acta*, 2011, **706**, 8–24.
- 30 J. Grand, B. Auguié and E. C. Le Ru, *Anal. Chem.*, 2019, **91**(22), 14639–14648.
- 31 D. A. Selvan, D. Mahendiran, R. S. Kumar and A. K. Rahiman, *J. Photochem. Photobiol., B*, 2018, **180**, 243–252.
- 32 L. Xing, H. Zhang, R. Qi, R. Tsao and Y. Mine, *J. Agric. Food Chem.*, 2020, **67**(4), 1029–1043.
- 33 H. Al Rashid, A. Kundu, V. Mandal, P. Wangchuk, and S. C. Mandal, *Herbal Medicine in India*, 2020, DOI: 10.1007/978-981-13-7248-3_39.
- 34 P. Singh, S. Pandit, J. Garnæs, S. Tunjic, V. R. Mokkaipati, A. Sultan, A. Thygesen, A. Mackevica, R. V. Mateiu, A. E. Daugaard and A. Baun, *Int. J. Nanomed.*, 2018, **13**, 3571.
- 35 S. Tang and J. Zheng, *Adv. Healthcare Mater.*, 2018, **7**(13), 1701503.
- 36 B. Le Ouay and F. Stellacci, *Nano Today*, 2015, **10**(3), 339–354.
- 37 A. K. Keshari, R. Srivastava, P. Singh, V. B. Yadav and G. Nath, *J. Ayurveda Integr. Med.*, 2020, **11**(1), 37–44.
- 38 H. Gandhi and S. Khan, *J. Nanomed. Nanotechnol.*, 2016, **7**(2), 1000366.
- 39 H. M. Ibrahim, *J. Radiat. Res. Appl. Sci.*, 2015, **8**(3), 265–275.

